Notification of Preliminary Results

RNS Number : 6173T

ReNeuron Group plc

04 July 2018

 

 

4 July 2018

AIM: RENE

ReNeuron Group plc

("ReNeuron" or the "Company")

Notification of Preliminary Results

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2018 on Thursday 12 July 2018.

A meeting for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

To access a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 10.00am on the day of the results:

http://webcasting.buchanan.uk.com/broadcast/5afc4a0b1fcda841bf20f48d 

A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.

ENDS

ENQUIRIES:

ReNeuron	[phone]
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited	[phone]
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)
N+1 Singer Advisory LLP	[phone]
Mark Taylor (Joint Broker)

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.   

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

NORLLFLVDIISIIT